<DOC>
	<DOCNO>NCT00331097</DOCNO>
	<brief_summary>The purpose study compare disease free survival elderly breast cancer patient treat standard adjuvant chemotherapy ( CMF ) versus experimental adjuvant chemotherapy ( weekly docetaxel ) .</brief_summary>
	<brief_title>ELDA : Elderly Breast Cancer - Docetaxel Adjuvant Treatment</brief_title>
	<detailed_description>Adjuvant combination chemotherapy , give breast cancer surgery , establish standard approach reduce risk breast cancer recurrence patient intermediate high risk recurrence . However , since elderly patient underrepresented past clinical trial , optimal adjuvant therapy elderly patient risk recurrence yet define . Docetaxel one active drug patient metastatic breast cancer several trial evaluate efficacy adjuvant setting . Administration docetaxel weekly schedule effective well tolerated woman metastatic breast cancer . In study , patient age 65 80 randomize one two treatment strategy : - standard adjuvant chemotherapy CMF ( cyclophosphamide , methotrexate , 5-fluorouracil give intravenously day 1 8 cycle ) - experimental adjuvant chemotherapy weekly docetaxel ( give intravenously day 1,8 , 15 cycle ) In treatment strategy : - 4 cycle chemotherapy administer patient least 10 % positive ER PgR , 6 cycle administer patient express &lt; 10 % ER PgR - patient positive expression ER PgR receive adjuvant hormonal therapy tamoxifen ( 20mg/day 5 year ) conclude chemotherapy - adjuvant radiation therapy give patient candidate conclusion chemotherapy within 6 month surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm invasive unilateral breast cancer Age &gt; 65 &lt; 80 year Intermediatehigh risk recurrence accord St. Gallen criterion : ER negative PgR negative , axillary lymph node metastasis , tumor size &gt; 2 cm , tumor grade 2 3 ( intermediate high ) Performance status &gt; 1 Distant metastasis Concomitant malignancy malignancy within previous 5 year ( except basal cell spinocellular skin cancer situ cervical cancer adequately treat Previous breast cancer treatment Neutrophils &lt; 2000/mm3 platelet &lt; 100000/mm3 haemoglobin &lt; 10 g/dl Creatinine &gt; 1.25 upper normal limit GOT andor GPT and/or bilirubin &gt; 1.25 upper normal limit Concomitant condition contraindicate use drug protocol Incapacity refusal provide inform consent</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>elderly</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>intermediate risk</keyword>
	<keyword>high risk</keyword>
</DOC>